CytoVeris is developing TumorMAP, an AI-powered cancer imaging technology that can deliver real-time cancer tissue visualization, enabling more precise intraoperative decisions and improving patient outcomes. TumorMAP uses multispectral scans, sent through the body at different wavelengths. They return 16 photos, which are fed into their AI. After only minutes, the computer tells doctors exactly where tumor masses exist in the body. They believe the platform technology could eventually be applied to any tumor mass, but they are currently pursuing approval for bladder cancer. A common treatment for bladder cancer involves scraping the cancerous cells from the inside of the bladder, called a TURBT procedure. Unfortunately doctors often miss cells, meaning many of the 600,000 procedures per year in the US are return surgeries. TumorMAP would allow doctors to check for cancerous masses in real time, eliminating the need for those second surgeries. While they enter Phase III trials for approval on bladder cancer, they are beginning to teach their AI algorithm to recognize tumor masses in the prostate. This will be further bolstered by their robotics partnership with Dr Vipul Patel, one of the most experienced robotics surgeons in the country.


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.